Market Analysis – Insight & Trends
As CBD interest continues to grow among consumers the need to differentiate products within the marketplace is becoming a significant factor for both existing manufacturers and new entrants. Genotyping offers a distinctive advantage when it comes to the marketing and development of CBD products by allowing precision formulations and accurate dosage instructions to be personalised to the individual.
The amount of CBD you should take depends on a range of factors, including: Body weight; the condition that the product is being used for; your individual body chemistry; and, the concentration of the CBD in each dose.
A 2017 review of a range of research studies found that there is not one universal dosage of CBD that everyone should take. Instead, it underscored the fact that different people (and, in the animal studies, different animals) respond to different dosages of CBD. Most of the human studies use dosages anywhere between 20 and 1,500 milligrams (mg) per day.
When a person takes CBD, the way that the body absorbs that chemical, and then responds, is managed by the an important neuromodulatory system in the body which has become known as the endocannabinoid system (ECS). Each person’s ECS response can be different and as a result the impact of a particular dose of CBD will similarly vary from person to person.
Genotyping, the analysis of someone’s genotype using DNA-testing, provides researchers with a way of determining more accurately how an individual’s body might respond to the application or consumption of CBD. In turn this data can be used to develop products formulated specifically for an individual’s own genetic composition, and the dosage can be calculated to ensure that it is both delivered, and absorbed, at an optimal level.
This type of precision product development mirrors moves from the wider medical and pharmaceutical sectors, where increasingly tailored medications are being developed to treat patients on an individual basis.
There are now similar moves to offer targeted formulations for the commercial CBD market.
US-based Endocanna is a biotechnology research company that utilises a patent-pending genotyping process for its CBD DNA variant report, Endo·Decoded™ and product matching algorithm, Endo·Aligned™. Endo·dna™ provides two ways to submit DNA for analysis, either collected through a simple saliva swab or a direct upload of genetic data files from popular DNA testing services like Ancestry, 23andMe, Family TreeDNA, or MyHeritageDNA.
Endocanna’s HIPAA compliant and secure health and wellness portal, Mydna.live, provides customers with a personalised experience where they can access their Endo·Decoded report and Endo·Aligned CBD formulation suggestions for their specific genotype.
The company has recently partner with New Coastal to offer a unique DNA test that identifies the exact CBD product that will provide the optimal level of wellness for each individual person.
In January, New Coastal Group launched Endo-Aligned™ CBD Tinctures and Softgels for targeted usage. The Endo-Aligned™ cannabinoid formulations are based on the analysis of the genotype groupings from more than 100 genetic biomarkers, the tinctures and softgels then use nanoemulsion to increase absorption rate.
“Our relationship with New Coastal provides an opportunity for EndoCanna Health to identify and develop optimal products for individual genotypes, while advancing the science of CBD and genomics,” said Len May, CEO & Co-Founder of EndoCanna Health, Inc. “Using the Endo-dna™patent pending bio-technology, we can identify and formulate a personalized CBD protocol tailored to an individual’s needs.”
The formulations provide a system of product evaluation based on over 20 years of science and the analysis of individual DNA, as well as precision endocannabinoid medicine. The idea was created and developed based on genetic research, peer-reviewed scientific papers and real-world experience. It was conceived to remove the ambiguity and stress that most people feel when searching for the best CBD or cannabinoid for individual health and wellness goals.
The tinctures and softgels are made with specific formulas to help with the three biggest ailments facing Americans today, including: Muscle soreness and inflammation support; Stress and Anxiety; and Sleep support.
This partnership represents the first in what will likely become a new segment of precision CBD products.
The alignment of DNA-testing and personalised formulation services, is an example of how we will see, in the near future, CBD manufacturers increasingly combining services like testing, personal consultation, technology-enabled support in order to differentiate products and improve customer/brand loyalty within a crowded marketplace.